Back to top
more

Illumina (ILMN)

(Delayed Data from NSDQ)

$149.76 USD

149.76
1,714,060

+5.62 (3.90%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $149.78 +0.02 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Illumina (ILMN) Advances in NGS With DRAGEN v4.3 Launch

by Zacks Equity Research

One of the standout features of Illumina's (ILMN) DRAGEN v4.3 is its machine-learning mosaic model.

The Zacks Analyst Blog Highlights Union Pacific, Freeport-McMoRan, Block, Xcel and Illumina

by Zacks Equity Research

Union Pacific, Freeport-McMoRan, Block, Xcel and Illumina are included in this Analyst Blog.

Sheraz Mian headshot

Top Research Reports for Union Pacific, Freeport-McMoRan & Block

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Union Pacific Corporation (UNP), Freeport-McMoRan Inc. (FCX) and Block, Inc. (SQ).

Illumina (ILMN) Q1 Earnings Beat, Adjusted Operating Loss Widens

by Zacks Equity Research

Illumina (ILMN) surpasses expectations in the first quarter in a challenging global macroeconomic environment.

Illumina (ILMN) Reports Q1 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

Although the revenue and EPS for Illumina (ILMN) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Urmimala Biswas headshot

Will These 5 MedTech Stocks Beat Forecasts This Earnings Season?

by Urmimala Biswas

Here is a sneak peek into how the five MedTech stocks, HOLX, ZBH, ILMN, TFX and BRKR, are expected to fare in their quarterly results slated to be released tomorrow.

Analysts Estimate AbCellera Biologics Inc. (ABCL) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

AbCellera Biologics (ABCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Gear Up for Illumina (ILMN) Q1 Earnings: Wall Street Estimates for Key Metrics

by Zacks Equity Research

Evaluate the expected performance of Illumina (ILMN) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Illumina (ILMN) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Illumina (ILMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

by Zacks Equity Research

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Can Illumina (ILMN) Keep the Earnings Surprise Streak Alive?

by Zacks Equity Research

Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

by Zacks Equity Research

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

by Zacks Equity Research

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Exact Sciences (EXAS) Up 4.2% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Is Invesco S&P 500 Equal Weight Health Care ETF (RSPH) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for RSPH

Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?

by Zacks Equity Research

Sector ETF report for PBE

Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RSPH)?

by Zacks Equity Research

Sector ETF report for RSPH

Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for PBE

Should Invesco S&P 500 Equal Weight ETF (RSP) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for RSP

Is Invesco S&P 500 Equal Weight ETF (RSP) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for RSP

Illumina (ILMN) Rides on NGS Portfolio Expansion Amid Macro Woe

by Zacks Equity Research

In reproductive health, Illumina (ILMN) primarily focuses on driving noninvasive prenatal testing (NIPT) adoption globally.

Illumina (ILMN) Q4 Earnings Surpass Estimates, Margin Down

by Zacks Equity Research

Illumina (ILMN) Q4 revenues increase year over year, driven by NovaSeq X instrument and consumables sales.

Illumina (ILMN) Reports Q4 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

While the top- and bottom-line numbers for Illumina (ILMN) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

HRMY or ILMN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

HRMY vs. ILMN: Which Stock Is the Better Value Option?

Seeking Clues to Illumina (ILMN) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics

by Zacks Equity Research

Get a deeper insight into the potential performance of Illumina (ILMN) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.